摘要
克里米亚–刚果出血热病毒(Crimean-Congo hemorrhagic fever virus,CCHFV)是一种布尼亚病毒目内罗病毒科正内罗病毒属、蜱虫传播的负链RNA病毒,能引起严重的出血热,病死率约为30%。目前临床上尚无针对CCHFV的疫苗和抗病毒药物,因此,各国普遍将CCHFV列为生物安全风险等级最高的病原之一,世界卫生组织也连续多年将其列入优先研究病原名录。然而,自1956年CCHFV被发现以来,其受体一直未被鉴定。该研究团队根据CCHFV感染细胞的特点进行分析,通过筛选发现低密度脂蛋白受体(low density lipoprotein receptor,LDLR)是CCHFV的一个入侵受体。该受体的发现,对CCHFV感染致病机制的理解和防控策略的研发具有重要的科学意义和应用价值。
CCHFV(Crimean-Congo hemorrhagic fever virus),a member of the Orthonairovirus genus in the Nairoviridae family of the Bunyavirales order,is a tick-borne RNA virus that causes severe hemorrhagic dis-ease in humans,with fatality rate around 30%.It has been shortlisted as a priority pathogen according to the WHO R&D Blueprint.So far,there is no effective antivirals or vaccines for CCHFV infection.For more than 60 years since the discovery of CCHFV,the cellular entry receptor(s)have not yet been identified.In this study,WANG and colleagues have identified LDLR(low density lipoprotein receptor)as an entry receptor for CCHFV.This study will not only shed light on the mechanism of CCHFV infection,but also provide antiviral targets and potential therapeu-tic strategies against CCHFV.
作者
徐智圣
王延轶
XU Zhisheng;WANG Yanyi(State Key Laboratory of Virology,Wuhan Institute of Virology,Chinese Academy of Sciences,Wuhan 430207,China)
出处
《中国细胞生物学学报》
CAS
CSCD
2024年第3期373-377,共5页
Chinese Journal of Cell Biology
基金
国家重点研发计划(批准号:2023YFC2306100,2022YFC2303302)
国家自然科学基金联合基金重点项目(批准号:U23A20168)
中国科学院战略性先导科技专项(批准号:XDB0490000,XDB29010302)
湖北省重大科技专项(批准号:2022ACA005)资助的课题。